From now on, the platform, sold as the 8500 Affinity Chip Analyzer by ABI, will be marketed by HTS Biosystems as the Flexchip Kinetic Analysis System.
As a result of its ongoing business review, ABI decided to stop selling the instrument. "Although we have had a successful relationship with Applied Biosystems, we understand their future market emphasis, and agree that the Flexchip system's success is best served through specific market focus by HTS," said Gregory Freitag, HTS' CEO, in a company statement.
The two companies first agreed to bring the instrument to market in 2002.